Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European Consensus

Antibiotiques

Volumn 3, Issue 1, 2001, Pages 50-68

  Doring G ^a   Bergogne Berezin F E ^a  

^a Redacteur Chef Antibiot Masson   (France)

Author keywords

Antibiotic therapy; Cystic fibrosis; Microbial resistance; Monotherapy; Nebulized antibiotics; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; MEROPENEM; NETILMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN;

AIRWAY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AUTOSOMAL RECESSIVE INHERITANCE; BACTERIAL COLONIZATION; CAUCASIAN; CHRONIC RESPIRATORY TRACT DISEASE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CYSTIC FIBROSIS; EVIDENCE BASED MEDICINE; GENETIC DISORDER; GRAM NEGATIVE INFECTION; HOME CARE; HOSPITAL CARE; HUMAN; LUNG INFECTION; MAINTENANCE THERAPY; MEDICAL EXPERT; MONOTHERAPY; NEBULIZATION; PHARMACOKINETICS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SIDE EFFECT;

EID: 0035100796     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (144)

1. The epidemiology of cystic fibrosis
2. Basic molecular biology
3. The pathology of cystic fibrosis
4. Lower airway inflammation in infants and young children with cystic fibrosis
5. Early pulmonary inflammation in infants with cystic fibrosis
6. Epidemiology and ecology of Pseudomonas aeruginosa
7. Microbiology of lung infections in cystic fibrosis patients
8. Denmark to the rescue
9. Pseudomonas aeruginosa infection in cystic fibrosis and its management
10. Pseudomonas aeruginosa vaccines
11. Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis - Three year results
12. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis
13. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis
14. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis
15. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
16. Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages
17. Immunology of cystic fibrosis
18. Pseudomonas and Burkholderia
19. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa
20. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis
21. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients
22. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis
23. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients
24. Progression of pulmonary disease after disappearance of Pseudomonas in cystic fibrosis
25. Determinants of mortality from cystic fibrosis in Canada, 1970-1989
26. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
27. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis
28. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
29. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
30. Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment
31. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
32. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms
33. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment
34. Imipenem/ cilastatin in acute pulmonary exacerbations of cystic fibrosis
35. Antibacterial therapy in cystic fibrosis. A review of the literature published between 1980 and February 1987
36. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
37. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
38. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
39. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis
40. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
41. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin dose for Pseudomonas exacerbations in cystic fibrosis
42. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis
43. Long-term tobramycin therapy in cystic fibrosis
44. Tobramycin aerosol: Could the delivery system influence the particle size and deposition in the lower airways?
45. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center
46. Antibiotic resistance of Pseudomonas aeruginosa
47. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
48. What is an antibiotic?
49. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis
50. Development of Pseudomonas aeruginosa strains resistant to carbenicillin, azlocillin, piperacillin and tobramycin during chemotherapy in cystic fibrosis patients
51. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance
52. Pharmacokinetics of quinolones with special reference to the respiratory tree
53. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree
54. Pharmacokinetics of antibiotics in the lungs
55. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions
56. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients
57. Pharmacokinetics of antimicrobial drugs in cystic fibrosis; β-lactam antibiotics
58. Pharmacokinetics of ciprofloxacin in cystic fibrosis
59. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis
60. Four years' experience of intravenous colimycin in an adult cystic fibrosis unit
61. Macromolecular mechanisms of sputum inhibition of tobramycin activity
62. Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study
63. Antibiotic activity in sputum
64. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum
65. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis
66. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro
67. Interference of ciprofloxacin with the expression of pathogenicity factors of Pseudomonas aeruginosa
68. Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations
69. Pseudomonas aeruginosa virulence factors: Modifications by sub-inhibitory concentrations of carbenicillin or gentamicin
70. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant Pseudomonas
71. Pharmacokinetics of meropenem in patients with cystic fibrosis
72. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study
73. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis
74. Drug disposition in cystic fibrosis: Progress in understanding pathophysiology and pharmacokinetics
75. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment
76. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis
77. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
78. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis
79. Amoniglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
80. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin
81. Lung disease in cystic fibrosis-an updated concept
82. Continous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology and pharmacokinetics
83. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fib-rosis
84. Adverse reactions to piperacillin in adults with cystic fibrosis
85. Cummulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis
86. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis
87. Ceftazidime, gentamicin and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa
88. Long-term azithromycin may improve lung function in children with cystic fibrosis. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides
89. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides
90. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms
91. Carbenicillin in patients with cystic fibrosis: Clinical pharmacology and therapeutic evaluation
92. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis
93. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: Effects of tobramycin
94. Symptomatic hypomagnesaemia in cystic fibrosis
95. Comparative nephrotoxicity of gentamicin and tobramycin: Pharmacokinetic and clinical studies in 201 patients
96. Evaluation of a once-daily netilmicin regimen in the treatment of cystic fibrosis
97. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other β-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses
98. Drug allergy in cystic fibrosis
99. Increasing dose regimen in children with reactions to ceftazidime
100. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
101. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis
102. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
103. Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
104. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis
105. Quinolone arthropathy in animals versus children
106. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging
107. Use of fluoroquinolones in pediatrics: Consensus report of an international society of chemotherapy commission
108. Inhalation of antibiotics in cystic fibrosis
109. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa in cystic fibrosis: Current status of the host-bacterium interaction
110. Nebulized gentamicin in children and adolescents with cystic fibrosis
111. Nebulised colimycin for early Pseudomonas colonisation in cystic fibrosis
112. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis
113. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks
114. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
115. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis
116. Evidence for using nebulised antibiotics in cystic fibrosis
117. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis
118. Bronchial response to nebulized antibiotics in children with cystic fibrosis
119. Nebulized colistin causes chest tightness in adults with cystic fibrosis
120. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis
121. Nebulizer delivery of tobramycin to the lower respiratory tract
122. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
123. Inhaled micronised gentamicin powder: A new delivery system
124. Effect of nebulizer type and antibiotic concentration on device performance
125. Therapeutic aerosols 1. Physical and practical considerations
126. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols
127. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand
128. Quantitative deposition of aerosolized gentamicin in cystic fibrosis
129. The quantitative distribution of nebulised antibiotic in the lung in cystic fibrosis
130. Homogeneity of bronchopulmonary distribution of 99Tc aerosol in normal subjects and in cystic fibrosis patients
131. In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis
132. Nebulised antibiotics for adults with cystic fibrosis
133. The carbenicillin potentiating effect of N-acetylcysteine in vitro
134. Recombinant human DNAse I reduces the viscosity of cystic fibrosis sputum
135. N-acetylcysteine and 2-mercaptoethane sulphonate inhibit anti-pseudomonas activity of antibiotics in vitro
136. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation
137. Prognosis in cystic fibrosis treated with continous flucloxacillin from the neonatal period
138. Home intravenous therapy in cystic fibrosis: A prospective randomized trial examining clinical, quality of life and cost aspects
139. Home nebulizer use among patients with cystic fibrosis
140. Treatment of exacerbations only does not arrest progressive lung function decline in CF
141. Aerosoltherapie et mucoviscidose: Enquete nationale
142. Safely of aerosol tobramycin administration for 3 months to patients with cystic fibrosis